Cargando…
The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders
Until now, models of psychiatric diseases have typically been animal models. Whether they were to be used to further understand the pathophysiology of the disorder, or as drug discovery tools, animal models have been the choice of preference in mimicking psychiatric disorders in an experimental sett...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932164/ https://www.ncbi.nlm.nih.gov/pubmed/23839283 http://dx.doi.org/10.1007/s00213-013-3196-4 |
_version_ | 1782304755203178496 |
---|---|
author | Cocks, Graham Curran, Sarah Gami, Priya Uwanogho, Dafe Jeffries, Aaron R. Kathuria, Annie Lucchesi, Walter Wood, Victoria Dixon, Rosemary Ogilvie, Caroline Steckler, Thomas Price, Jack |
author_facet | Cocks, Graham Curran, Sarah Gami, Priya Uwanogho, Dafe Jeffries, Aaron R. Kathuria, Annie Lucchesi, Walter Wood, Victoria Dixon, Rosemary Ogilvie, Caroline Steckler, Thomas Price, Jack |
author_sort | Cocks, Graham |
collection | PubMed |
description | Until now, models of psychiatric diseases have typically been animal models. Whether they were to be used to further understand the pathophysiology of the disorder, or as drug discovery tools, animal models have been the choice of preference in mimicking psychiatric disorders in an experimental setting. While there have been cellular models, they have generally been lacking in validity. This situation is changing with the advent of patient-specific induced pluripotent stem cells (iPSCs). In this article, we give a methodological evaluation of the current state of the iPS technology with reference to our own work in generating patient-specific iPSCs for the study of autistic spectrum disorder (ASD). In addition, we will give a broader perspective on the validity of this technology and to what extent it can be expected to complement animal models of ASD in the coming years. |
format | Online Article Text |
id | pubmed-3932164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-39321642014-02-28 The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders Cocks, Graham Curran, Sarah Gami, Priya Uwanogho, Dafe Jeffries, Aaron R. Kathuria, Annie Lucchesi, Walter Wood, Victoria Dixon, Rosemary Ogilvie, Caroline Steckler, Thomas Price, Jack Psychopharmacology (Berl) Theoretical and Methodological Perspectives Until now, models of psychiatric diseases have typically been animal models. Whether they were to be used to further understand the pathophysiology of the disorder, or as drug discovery tools, animal models have been the choice of preference in mimicking psychiatric disorders in an experimental setting. While there have been cellular models, they have generally been lacking in validity. This situation is changing with the advent of patient-specific induced pluripotent stem cells (iPSCs). In this article, we give a methodological evaluation of the current state of the iPS technology with reference to our own work in generating patient-specific iPSCs for the study of autistic spectrum disorder (ASD). In addition, we will give a broader perspective on the validity of this technology and to what extent it can be expected to complement animal models of ASD in the coming years. Springer Berlin Heidelberg 2013-07-10 2014 /pmc/articles/PMC3932164/ /pubmed/23839283 http://dx.doi.org/10.1007/s00213-013-3196-4 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Theoretical and Methodological Perspectives Cocks, Graham Curran, Sarah Gami, Priya Uwanogho, Dafe Jeffries, Aaron R. Kathuria, Annie Lucchesi, Walter Wood, Victoria Dixon, Rosemary Ogilvie, Caroline Steckler, Thomas Price, Jack The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders |
title | The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders |
title_full | The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders |
title_fullStr | The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders |
title_full_unstemmed | The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders |
title_short | The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders |
title_sort | utility of patient specific induced pluripotent stem cells for the modelling of autistic spectrum disorders |
topic | Theoretical and Methodological Perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932164/ https://www.ncbi.nlm.nih.gov/pubmed/23839283 http://dx.doi.org/10.1007/s00213-013-3196-4 |
work_keys_str_mv | AT cocksgraham theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT curransarah theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT gamipriya theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT uwanoghodafe theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT jeffriesaaronr theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT kathuriaannie theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT lucchesiwalter theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT woodvictoria theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT dixonrosemary theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT ogilviecaroline theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT stecklerthomas theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT pricejack theutilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT cocksgraham utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT curransarah utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT gamipriya utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT uwanoghodafe utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT jeffriesaaronr utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT kathuriaannie utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT lucchesiwalter utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT woodvictoria utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT dixonrosemary utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT ogilviecaroline utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT stecklerthomas utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders AT pricejack utilityofpatientspecificinducedpluripotentstemcellsforthemodellingofautisticspectrumdisorders |